v3.10.0.1
Segment, Geographic and Other Revenue Information (Tables)
 12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

 
2016

 
2018

 
2017

 
2016

 
2018

 
2017

 
2016

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IH(c)
 
$
33,426

 
$
31,422

 
$
29,197

 
$
20,258

 
$
18,809

 
$
16,166

 
$
629

 
$
534

 
$
583

EH(c)
 
20,221

 
21,124

 
23,627

 
10,712

 
11,460

 
13,065

 
547

 
579

 
600

Total reportable segments
 
53,647

 
52,546

 
52,824

 
30,970

 
30,269

 
29,231

 
1,175

 
1,113

 
1,183

Other business activities(d), (e)
 
—

 
—

 
—

 
(2,977
)
 
(3,137
)
 
(3,020
)
 
93

 
90

 
85

Reconciling Items:
 
 

 
 

 


 
 

 
 

 


 


 


 


Corporate(c), (e)
 
—

 
—

 
—

 
(5,096
)
 
(5,452
)
 
(5,448
)
 
363

 
337

 
356

Purchase accounting adjustments(e)
 
—

 
—

 
—

 
(4,786
)
 
(4,758
)
 
(4,185
)
 
4,620

 
4,565

 
3,890

Acquisition-related costs(e)
 
—

 
—

 
—

 
(318
)
 
(456
)
 
(785
)
 
12

 
39

 
7

Certain significant items(f)
 
—

 
—

 
—

 
(4,305
)
 
(2,647
)
 
(5,888
)
 
38

 
52

 
200

Other unallocated(c), (e)
 
—

 
—

 
—

 
(1,603
)
 
(1,514
)
 
(1,554
)
 
82

 
72

 
35

 
 
$
53,647

 
$
52,546

 
$
52,824

 
$
11,885

 
$
12,305

 
$
8,351

 
$
6,384

 
$
6,269

 
$
5,757

(a) 
Income from continuing operations before provision/(benefit) for taxes on income. IH’s earnings include dividend income from our investment in ViiV of $253 million in 2018 and $266 million in 2017. For additional information, see Note 4.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
In connection with the StratCO reporting change, in 2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.
(d) 
Other business activities includes the costs managed by our WRD and GPD organizations.
(e) 
For a description, see the “Other Costs and Business Activities” section above.
(f) 
Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million, (ii) net charges for certain legal matters of $157 million, (iii) income of $1 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $3.1 billion, (v) charges for business and legal entity alignment of $4 million, (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $65 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the legislation commonly referred to as the TCJA, $59 million of incremental costs associated with the design, planning and implementation of the new organizational structure, effective in the beginning of 2019, and primarily including consulting, legal, tax, and advisory services and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4.
For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million, (ii) charges for certain legal matters of $237 million, (iii) charges of $55 million, representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $379 million, (v) charges for business and legal entity alignment of $71 million, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $700 million. For additional information, see Note 2B, Note 3 and Note 4.
For Earnings in 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.4 billion, (ii) charges for certain legal matters of $494 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion, (iv) certain asset impairment charges of $1.4 billion, (v) charges for business and legal entity alignment of $261 million, (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $294 million. For additional information, see Note 3 and Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

 
2016

 
2018

 
2017

 
2016

 
2018

 
2017

 
2016

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IH(c)
 
$
33,426

 
$
31,422

 
$
29,197

 
$
20,258

 
$
18,809

 
$
16,166

 
$
629

 
$
534

 
$
583

EH(c)
 
20,221

 
21,124

 
23,627

 
10,712

 
11,460

 
13,065

 
547

 
579

 
600

Total reportable segments
 
53,647

 
52,546

 
52,824

 
30,970

 
30,269

 
29,231

 
1,175

 
1,113

 
1,183

Other business activities(d), (e)
 
—

 
—

 
—

 
(2,977
)
 
(3,137
)
 
(3,020
)
 
93

 
90

 
85

Reconciling Items:
 
 

 
 

 


 
 

 
 

 


 


 


 


Corporate(c), (e)
 
—

 
—

 
—

 
(5,096
)
 
(5,452
)
 
(5,448
)
 
363

 
337

 
356

Purchase accounting adjustments(e)
 
—

 
—

 
—

 
(4,786
)
 
(4,758
)
 
(4,185
)
 
4,620

 
4,565

 
3,890

Acquisition-related costs(e)
 
—

 
—

 
—

 
(318
)
 
(456
)
 
(785
)
 
12

 
39

 
7

Certain significant items(f)
 
—

 
—

 
—

 
(4,305
)
 
(2,647
)
 
(5,888
)
 
38

 
52

 
200

Other unallocated(c), (e)
 
—

 
—

 
—

 
(1,603
)
 
(1,514
)
 
(1,554
)
 
82

 
72

 
35

 
 
$
53,647

 
$
52,546

 
$
52,824

 
$
11,885

 
$
12,305

 
$
8,351

 
$
6,384

 
$
6,269

 
$
5,757

(a) 
Income from continuing operations before provision/(benefit) for taxes on income. IH’s earnings include dividend income from our investment in ViiV of $253 million in 2018 and $266 million in 2017. For additional information, see Note 4.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
In connection with the StratCO reporting change, in 2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.
(d) 
Other business activities includes the costs managed by our WRD and GPD organizations.
(e) 
For a description, see the “Other Costs and Business Activities” section above.
(f) 
Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million, (ii) net charges for certain legal matters of $157 million, (iii) income of $1 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $3.1 billion, (v) charges for business and legal entity alignment of $4 million, (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $65 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the legislation commonly referred to as the TCJA, $59 million of incremental costs associated with the design, planning and implementation of the new organizational structure, effective in the beginning of 2019, and primarily including consulting, legal, tax, and advisory services and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4.
For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million, (ii) charges for certain legal matters of $237 million, (iii) charges of $55 million, representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $379 million, (v) charges for business and legal entity alignment of $71 million, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $700 million. For additional information, see Note 2B, Note 3 and Note 4.
For Earnings in 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.4 billion, (ii) charges for certain legal matters of $494 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion, (iv) certain asset impairment charges of $1.4 billion, (v) charges for business and legal entity alignment of $261 million, (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $294 million. For additional information, see Note 3 and Note 4.
Reconciliation Of Depreciation And Amortization From Segments To Consolidated
The following table provides selected income statement information by reportable segment:
 
 
Revenues
 
Earnings(a)
 
Depreciation and Amortization(b)
 
 
Year Ended December 31,
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

 
2016

 
2018

 
2017

 
2016

 
2018

 
2017

 
2016

Reportable Segments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IH(c)
 
$
33,426

 
$
31,422

 
$
29,197

 
$
20,258

 
$
18,809

 
$
16,166

 
$
629

 
$
534

 
$
583

EH(c)
 
20,221

 
21,124

 
23,627

 
10,712

 
11,460

 
13,065

 
547

 
579

 
600

Total reportable segments
 
53,647

 
52,546

 
52,824

 
30,970

 
30,269

 
29,231

 
1,175

 
1,113

 
1,183

Other business activities(d), (e)
 
—

 
—

 
—

 
(2,977
)
 
(3,137
)
 
(3,020
)
 
93

 
90

 
85

Reconciling Items:
 
 

 
 

 


 
 

 
 

 


 


 


 


Corporate(c), (e)
 
—

 
—

 
—

 
(5,096
)
 
(5,452
)
 
(5,448
)
 
363

 
337

 
356

Purchase accounting adjustments(e)
 
—

 
—

 
—

 
(4,786
)
 
(4,758
)
 
(4,185
)
 
4,620

 
4,565

 
3,890

Acquisition-related costs(e)
 
—

 
—

 
—

 
(318
)
 
(456
)
 
(785
)
 
12

 
39

 
7

Certain significant items(f)
 
—

 
—

 
—

 
(4,305
)
 
(2,647
)
 
(5,888
)
 
38

 
52

 
200

Other unallocated(c), (e)
 
—

 
—

 
—

 
(1,603
)
 
(1,514
)
 
(1,554
)
 
82

 
72

 
35

 
 
$
53,647

 
$
52,546

 
$
52,824

 
$
11,885

 
$
12,305

 
$
8,351

 
$
6,384

 
$
6,269

 
$
5,757

(a) 
Income from continuing operations before provision/(benefit) for taxes on income. IH’s earnings include dividend income from our investment in ViiV of $253 million in 2018 and $266 million in 2017. For additional information, see Note 4.
(b) 
Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) 
In connection with the StratCO reporting change, in 2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.
(d) 
Other business activities includes the costs managed by our WRD and GPD organizations.
(e) 
For a description, see the “Other Costs and Business Activities” section above.
(f) 
Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
For Earnings in 2018, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million, (ii) net charges for certain legal matters of $157 million, (iii) income of $1 million, representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $3.1 billion, (v) charges for business and legal entity alignment of $4 million, (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $65 million, which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling, informational and administrative expenses, for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the legislation commonly referred to as the TCJA, $59 million of incremental costs associated with the design, planning and implementation of the new organizational structure, effective in the beginning of 2019, and primarily including consulting, legal, tax, and advisory services and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B, Note 3 and Note 4.
For Earnings in 2017, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million, (ii) charges for certain legal matters of $237 million, (iii) charges of $55 million, representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $379 million, (v) charges for business and legal entity alignment of $71 million, (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $700 million. For additional information, see Note 2B, Note 3 and Note 4.
For Earnings in 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.4 billion, (ii) charges for certain legal matters of $494 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion, (iv) certain asset impairment charges of $1.4 billion, (v) charges for business and legal entity alignment of $261 million, (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $294 million. For additional information, see Note 3 and Note 4.
Revenue from External Customers by Geographic Areas
As described in Note 1A, the February 3, 2017 sale of HIS impacted our results of operations in 2018, 2017 and 2016.
The following table provides revenues by geographic area:
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
2018

 
2017

 
2016

United States
$
25,329

 
$
26,026

 
$
26,369

Developed Europe(a)
9,116

 
8,508

 
9,306

Developed Rest of World(b)
6,551

 
6,612

 
6,729

Emerging Markets (c)
12,651

 
11,399

 
10,420

Revenues
$
53,647

 
$
52,546

 
$
52,824


(a) 
Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.3 billion in 2018, $6.8 billion in 2017 and $7.2 billion in 2016.
(b) 
Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c) 
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Long-lived Assets by Geographic Areas
The following table provides long-lived assets by geographic area:
 
 
As of December 31,
(MILLIONS OF DOLLARS)
 
2018

 
2017

 
2016

Property, plant and equipment, net
 
 
 
 
 
 
United States
 
$
7,089

 
$
6,971

 
$
6,649

Developed Europe(a)
 
4,204

 
4,345

 
4,228

Developed Rest of World(b)
 
490

 
632

 
643

Emerging Markets(c)
 
1,602

 
1,917

 
1,797

Property, plant and equipment, net
 
$
13,385

 
$
13,865

 
$
13,318


(a) 
Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.
(b) 
Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c) 
Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues
As described in Note 1A, acquisitions and divestitures have impacted our results of operations in 2018, 2017 and 2016.
The following table provides detailed revenue information for several of our major products:
(MILLIONS OF DOLLARS)
 
 
 
Year Ended December 31,
PRODUCT
 
PRIMARY INDICATION OR CLASS
 
2018

 
2017

 
2016

TOTAL REVENUES
 
 
 
$
53,647

 
$
52,546

 
$
52,824

PFIZER INNOVATIVE HEALTH (IH)(a)
 
$
33,426

 
$
31,422

 
$
29,197

Internal Medicine
 
$
9,996

 
$
9,684

 
$
8,858

Lyrica IH(b)
 
Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury
 
4,622

 
4,511

 
4,165

Eliquis alliance revenues and direct sales
 
Atrial fibrillation, deep vein thrombosis, pulmonary embolism
 
3,434

 
2,523

 
1,713

Chantix/Champix
 
An aid to smoking cessation treatment in adults 18 years of age or older
 
1,085

 
997

 
842

BMP2
 
Development of bone and cartilage
 
279

 
261

 
251

Toviaz
 
Overactive bladder
 
271

 
257

 
258

Viagra IH(c)
 
Erectile dysfunction
 
—

 
823

 
1,181

All other Internal Medicine
 
Various
 
306

 
312

 
447

Vaccines
 
$
6,332

 
$
6,001

 
$
6,071

Prevnar 13/Prevenar 13
 
Vaccines for prevention of pneumococcal disease
 
5,802

 
5,601

 
5,718

FSME/IMMUN-TicoVac
 
Tick-borne encephalitis vaccine
 
184

 
134

 
114

Trumenba
 
Meningococcal Group B vaccine
 
116

 
88

 
84

All other Vaccines
 
Various
 
230

 
177

 
155

Oncology
 
$
7,202

 
$
6,056

 
$
4,563

Ibrance
 
Advanced breast cancer
 
4,118

 
3,126

 
2,135

Sutent
 
Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor
 
1,049

 
1,081

 
1,095

Xtandi alliance revenues
 
Castration-resistant prostate cancer
 
699

 
590

 
140

Xalkori
 
ALK-positive and ROS1-positive advanced NSCLC
 
524

 
594

 
561

Inlyta
 
Advanced RCC
 
298

 
339

 
401

Bosulif
 
Philadelphia chromosome–positive chronic myelogenous leukemia
 
296


233


167

All other Oncology
 
Various
 
219

 
93

 
63

Inflammation & Immunology (I&I)
 
$
4,080

 
$
3,968

 
$
3,928

Enbrel (Outside the U.S. and Canada)
 
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
 
2,112

 
2,452

 
2,909

Xeljanz
 
RA, PsA, ulcerative colitis
 
1,774

 
1,345

 
927

Eucrisa
 
Mild-to-moderate atopic dermatitis (eczema)
 
147


67


—

All other I&I
 
Various
 
46

 
103

 
93

Rare Disease
 
$
2,211

 
$
2,240

 
$
2,369

Genotropin
 
Replacement of human growth hormone
 
558

 
532

 
579

BeneFIX
 
Hemophilia
 
554

 
604

 
712

Refacto AF/Xyntha
 
Hemophilia
 
514

 
551

 
554

Somavert
 
Acromegaly
 
267

 
254

 
232

All other Rare Disease
 
Various
 
318

 
300

 
292

Consumer Healthcare
 
 
 
$
3,605

 
$
3,472

 
$
3,407

PFIZER ESSENTIAL HEALTH (EH)(d)
 
$
20,221

 
$
21,124

 
$
23,627

Legacy Established Products (LEP)(e)
 
$
10,540

 
$
10,894

 
$
11,197

Lipitor
 
Reduction of LDL cholesterol
 
2,062

 
1,915

 
1,758

Norvasc
 
Hypertension
 
1,024

 
926

 
962

Premarin family
 
Symptoms of menopause
 
832

 
977

 
1,017

Xalatan/Xalacom
 
Glaucoma and ocular hypertension
 
318

 
335

 
363

Effexor
 
Depression and certain anxiety disorders
 
311

 
297

 
278

EpiPen
 
Epinephrine injection used in treatment of life-threatening allergic reactions
 
303

 
290

 
386

Zoloft
 
Depression and certain anxiety disorders
 
298

 
291

 
304

Zithromax
 
Bacterial infections
 
290

 
270

 
272

Xanax
 
Anxiety disorders
 
223

 
225

 
222

Sildenafil Citrate
 
Erectile dysfunction
 
56

 
56

 
—

All other LEP
 
Various
 
4,822

 
5,313

 
5,636

(MILLIONS OF DOLLARS)
 
 
 
Year Ended December 31,
PRODUCT
 
PRIMARY INDICATION OR CLASS
 
2018

 
2017

 
2016

Sterile Injectable Pharmaceuticals (SIP)(f)
 
$
5,214

 
$
5,673

 
$
6,014

Sulperazon
 
Treatment of infections
 
613

 
471

 
396

Medrol
 
Steroid anti-inflammatory
 
427

 
483

 
450

Fragmin
 
Slows blood clotting
 
293

 
306

 
318

Tygacil
 
Tetracycline class antibiotic
 
249

 
260

 
274

Zosyn/Tazocin
 
Antibiotic
 
229

 
194

 
146

Precedex
 
Sedation agent in surgery or intensive care
 
213

 
243

 
264

All other SIP
 
Various
 
3,191

 
3,715

 
4,166

Peri-LOE Products(g)
 
$
2,944

 
$
3,223

 
$
4,220

Celebrex
 
Arthritis pain and inflammation, acute pain
 
686

 
775

 
733

Viagra EH(c)
 
Erectile dysfunction
 
636

 
382

 
383

Vfend
 
Fungal infections
 
392

 
421

 
590

Lyrica EH(b)
 
Epilepsy, neuropathic pain and generalized anxiety disorder
 
347

 
553

 
801

Zyvox
 
Bacterial infections
 
236

 
281

 
421

Revatio
 
Pulmonary arterial hypertension
 
227

 
252

 
285

Pristiq
 
Depression
 
206

 
303

 
732

All other Peri-LOE Products
 
Various
 
213

 
257

 
276

Biosimilars(h)
 
Various
 
$
769

 
$
531

 
$
319

Inflectra/Remsima
 
Inflammatory diseases
 
642

 
419

 
192

All other Biosimilars
 
Various
 
127

 
112

 
127

Pfizer CentreOne(i)
 
 
 
$
755

 
$
706

 
$
718

Hospira Infusion Systems (HIS)(j)
 
Various
 
$
—

 
$
97

 
$
1,158

Total Lyrica(b)
 
Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury
 
$
4,970

 
$
5,065

 
$
4,966

Total Viagra(c)
 
Erectile dysfunction
 
$
636

 
$
1,204

 
$
1,564

Total Alliance revenues
 
Various
 
$
3,838

 
$
2,927

 
$
1,746

(a) 
The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
(b) 
Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
(c) 
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH. Total Viagra revenues in 2017 and 2016 represented the aggregate of worldwide revenues from Viagra IH and Viagra EH.
(d) 
The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).
(e) 
Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.
(f) 
Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
(g) 
Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017 and 2016), see note (c) above.
(h) 
Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in the U.S. and Retacrit (biosimilar epoetin zeta) in the U.S. and certain European and Africa/Middle Eastern markets.
(i) 
Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
(j) 
HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.